Morbus Alzheimer: Neues bei Therapie und Diagnose.

The article focuses on advancements in the treatment and diagnosis of Alzheimer's disease, with the U.S. Food Drug Administration (FDA) approving the first disease-modifying therapy, Lecanemab, in July 2023, along with another monoclonal antibody, Donanemab, expected to be approved by the EMA in the third quarter of 2024. It mentions therapies target amyloid plaques in the brain associated with nerve cell destruction while the article also discusses the evolving role of biomarkers.